Table 3.
Percentages of remission at baseline and 1-year follow-up and percentages of concomitant csDMARD and GC therapy in EST and NEW patients
| EST n = 284 | NEW n = 62 | |||
|---|---|---|---|---|
| baseline | after 1 year follow up | baseline | after 1 year follow up | |
| DAS28 remission % | 47.2 | 51.1 | 1.6 | 53.2 |
| RADAI-5 remission % | 31.3 | 36.3 | 1.6 | 27.4 |
| BC remisson % | 21.1 | 26.1 | 1.6 | 21.0 |
| GC% | 25.0 | 27.8 | 66.1 | 48.4 |
| csDMARD % | 56.0 | 51.8 | 83.9 | 67.7 |
| bDMARD % | 100.0 | 94.0 | na | 87.1 |
Abbreviations: BC Boolean criteria, bDMARD biologic DMARD, csDMARD conventional synthetic DMARD, DAS28 Disease Activity Score using ESR out of 28 joints, ESR Erythrocyte sedimentation rate, EST pts with established bDMARD treatment before inclusion in BIOREG of whom a full data set as described is viable, GC glucocorticoid; na not applicable, NEW pts included in BIOREG with start of biologic treatment ± 30 days; pts patients, RADAI-5 Rheumatoid Arthritis Disease Activity Index-5